Elena De Vita

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9435132/publications.pdf Version: 2024-02-01



Ει ενιά De Vita

#	Article	IF	CITATIONS
1	10 years into the resurgence of covalent drugs. Future Medicinal Chemistry, 2021, 13, 193-210.	2.3	66
2	Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry. Acta Neuropathologica Communications, 2018, 6, 21.	5.2	28
3	Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity. Journal of Medicinal Chemistry, 2018, 61, 8859-8874.	6.4	23
4	A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering. Journal of Biological Chemistry, 2018, 293, 12663-12680.	3.4	22
5	Synthesis and Structureâ€Activity Relationships of <i>N</i> â€(4â€Benzamidino)â€Oxazolidinones: Potent and Selective Inhibitors of Kallikreinâ€Related Peptidase 6. ChemMedChem, 2020, 15, 79-95.	3.2	16
6	A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate Cancer. Journal of the American Chemical Society, 2021, 143, 8911-8924.	13.7	14
7	Beyond targeted protein degradation: LD·ATTECs clear cellular lipid droplets. Cell Research, 2021, 31, 945-946.	12.0	8
8	Identification of the first structurally validated covalent ligands of the small GTPase RAB27A. RSC Medicinal Chemistry, 2022, 13, 150-155.	3.9	7
9	Blocking Kallikrein 6 promotes developmental myelination. Glia, 2022, 70, 430-450.	4.9	5
10	The Missing Link between (Un)druggable and Degradable KRAS. ACS Central Science, 2020, 6, 1281-1284.	11.3	4
11	Development of a fluorogenic ADAMTS-7 substrate. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 2160-2169.	5.2	4
12	Design and Synthesis of Ionic Liquidâ€Based Matrix Metalloproteinase Inhibitors (MMPIs): A Simple Approach to Increase Hydrophilicity and to Develop MMPIâ€Coated Gold Nanoparticles. ChemMedChem, 2019, 14, 686-698.	3.2	2